LTFS
OCUL icon

Ladenburg Thalmann Financial Services’s Ocular Therapeutix OCUL Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,100
Closed -$7K – 5256
2018
Q2 		$7K Hold
1,100
– – ﹤0.01% 4444
2018
Q1 		$7K Hold
1,100
– – ﹤0.01% 4444
2017
Q4 		$5K Buy
1,100
+1,000
+1,000% +$5.11K ﹤0.01% 4522
2017
Q3 		$1K Hold
100
– – ﹤0.01% 4808
2017
Q2 		$1K Sell
100
-400
-80% -$3.87K ﹤0.01% 4753
2017
Q1 		$5K Buy
+500
New +$4.16K ﹤0.01% 4316

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Ladenburg Thalmann Financial Services's OCUL Position: Q3 2018 in Review

Ladenburg Thalmann Financial Services sold out of Ocular Therapeutix (OCUL) in Q3 2018, closing a stake of 1,100 shares — an estimated $7K sold.

Ladenburg Thalmann Financial Services first reported a position in OCUL in Q1 2017 and held it in 6 quarters. The position peaked at $7K in Q2 2018. 73 funds tracked by Wall St. Rank hold OCUL as of Q3 2018.

  • Ladenburg Thalmann Financial Services reported no remaining Ocular Therapeutix position as of Q3 2018 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 1,100 Ocular Therapeutix shares in Q3 2018, an estimated $7K.
  • Ladenburg Thalmann Financial Services first reported a position in Ocular Therapeutix in Q1 2017 and held it in 6 quarters.
  • Ladenburg Thalmann Financial Services's Ocular Therapeutix position peaked at $7K in Q2 2018.
  • 73 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2018.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q3 2018, filed 14 Nov 2018.